Abstract
Investigation of the expression of glial fibrillary acidic protein (GFAP), a key marker of the functional state of astrocytes, in experimental modeling of diabetes mellitus (DM) is relevant due to the high incidence of diabetic encephalopathy in elderly patients with DM and the limited data on pathogenetic approaches to its therapy. Materials and methods: Using a model of type 1 DM induced by streptozotocin in 50 Wistar rats (aged 12 months), the effects of a 30-day course of aminalon (1000 mg/kg/day), succicard (50 mg/kg/day), and mefargin (20 mg/kg/day) were studied after 6 months of persistent hyperglycemia. GFAP expression in the hippocampus was assessed immunohistochemically followed by morphometry in ImageJ software and statistical analysis using ANOVA. Results and discussion: In the group of untreated diabetic animals, a significant decrease in the relative area of GFAP expression in hippocampal astrocytes was recorded compared to the intact control. Treatment with aminalon resulted in a larger area of immunoreactive material (IRM) in hippocampal neurons compared to diabetic animals. Animals receiving succicard also showed a larger area of IRM in hippocampal neurons compared to untreated diabetic animals. In diabetic animals treated with mefargin, a trend toward increased IRM was noted compared to material from untreated animals. Conclusion: Experimental DM leads to decreased GFAP expression in the hippocampus, indicating impaired astrocytic homeostasis and the involvement of glial cells in mechanisms of neuroinflammation in diabetic encephalopathy. GABA and its derivatives exert effects on astrocytes and promote the restoration of GFAP expression levels. The obtained results substantiate the promise of further investigation of GABA derivatives as agents for neuroprotection in cognitive disorders of diabetic origin.

This publication has 13 references indexed in Scilit: